253 related articles for article (PubMed ID: 34816762)
1. MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design.
Oskarsson B; Maragakis N; Bedlack RS; Goyal N; Meyer JA; Genge A; Bodkin C; Maiser S; Staff N; Zinman L; Olney N; Turnbull J; Brooks BR; Klonowski E; Makhay M; Yasui S; Matsuda K
Neurodegener Dis Manag; 2021 Dec; 11(6):431-443. PubMed ID: 34816762
[TBL] [Abstract][Full Text] [Related]
2. Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial.
Babu S; Hightower BG; Chan J; Zürcher NR; Kivisäkk P; Tseng CJ; Sanders DL; Robichaud A; Banno H; Evora A; Ashokkumar A; Pothier L; Paganoni S; Chew S; Dojillo J; Matsuda K; Gudesblatt M; Berry JD; Cudkowicz ME; Hooker JM; Atassi N
Neuroimage Clin; 2021; 30():102672. PubMed ID: 34016561
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study): Study protocol clinical trial (SPIRIT Compliant).
Vucic S; Ryder J; Mekhael L; Rd H; Mathers S; Needham M; Dw S; Mc K;
Medicine (Baltimore); 2020 Feb; 99(6):e18904. PubMed ID: 32028398
[TBL] [Abstract][Full Text] [Related]
4. G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial).
Salamone P; Fuda G; Casale F; Marrali G; Lunetta C; Caponnetto C; Mazzini L; La Bella V; Mandrioli J; Simone IL; Moglia C; Calvo A; Tarella C; Chio A;
BMJ Open; 2020 Mar; 10(3):e034049. PubMed ID: 32209625
[TBL] [Abstract][Full Text] [Related]
5. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.
Urbi B; Broadley S; Bedlack R; Russo E; Sabet A
BMJ Open; 2019 Nov; 9(11):e029449. PubMed ID: 31719072
[TBL] [Abstract][Full Text] [Related]
6. A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial.
Lombardo FL; Spila Alegiani S; Mayer F; Cipriani M; Lo Giudice M; Ludolph AC; McDermott CJ; Corcia P; Van Damme P; Van den Berg LH; Hardiman O; Nicolini G; Vanacore N; Dickie B; Albanese A; Puopolo M;
Trials; 2023 Dec; 24(1):792. PubMed ID: 38053196
[TBL] [Abstract][Full Text] [Related]
7. Study protocol of RESCUE-ALS: A Phase 2,
Vucic S; Kiernan MC; Menon P; Huynh W; Rynders A; Ho KS; Glanzman R; Hotchkin MT
BMJ Open; 2021 Jan; 11(1):e041479. PubMed ID: 33431491
[TBL] [Abstract][Full Text] [Related]
8. VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics.
Andrews JA; Cudkowicz ME; Hardiman O; Meng L; Bian A; Lee J; Wolff AA; Malik FI; Shefner JM
Amyotroph Lateral Scler Frontotemporal Degener; 2018 May; 19(3-4):259-266. PubMed ID: 29402141
[TBL] [Abstract][Full Text] [Related]
9. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial).
Mandrioli J; D'Amico R; Zucchi E; Gessani A; Fini N; Fasano A; Caponnetto C; Chiò A; Dalla Bella E; Lunetta C; Mazzini L; Marinou K; Sorarù G; de Biasi S; Lo Tartaro D; Pinti M; Cossarizza A;
Medicine (Baltimore); 2018 Jun; 97(24):e11119. PubMed ID: 29901635
[TBL] [Abstract][Full Text] [Related]
11. Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS).
Mandrioli J; Crippa V; Cereda C; Bonetto V; Zucchi E; Gessani A; Ceroni M; Chio A; D'Amico R; Monsurrò MR; Riva N; Sabatelli M; Silani V; Simone IL; Sorarù G; Provenzani A; D'Agostino VG; Carra S; Poletti A
BMJ Open; 2019 May; 9(5):e028486. PubMed ID: 31152038
[TBL] [Abstract][Full Text] [Related]
12. Randomized double-blind personalized N-of-1 clinical trial to test the safety and potential efficacy of TJ-68 for treating muscle cramps in amyotrophic lateral sclerosis (ALS): study protocol for a TJ-68 trial.
Mitsumoto H; Cheung K; Oskarsson B; Andrews HF; Jang GE; Andrews JA; Shah JS; Fernandes JA; McElhiney M; Santella RM
Trials; 2023 Jul; 24(1):449. PubMed ID: 37430314
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial.
Nam JY; Lee TY; Kim K; Chun S; Kim MS; Shin JH; Sung JJ; Kim BJ; Kim BJ; Oh KW; Kim KS; Kim SH
Trials; 2022 May; 23(1):415. PubMed ID: 35585556
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study.
de la Rubia JE; Drehmer E; Platero JL; Benlloch M; Caplliure-Llopis J; Villaron-Casales C; de Bernardo N; AlarcÓn J; Fuente C; Carrera S; Sancho D; GarcÍa-Pardo P; Pascual R; JuÁrez M; Cuerda-Ballester M; Forner A; Sancho-Castillo S; Barrios C; Obrador E; Marchio P; Salvador R; Holmes HE; Dellinger RW; Guarente L; Estrela JM
Amyotroph Lateral Scler Frontotemporal Degener; 2019 Feb; 20(1-2):115-122. PubMed ID: 30668199
[TBL] [Abstract][Full Text] [Related]
15. Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial).
Bella ED; Tramacere I; Antonini G; Borghero G; Capasso M; Caponnetto C; Chiò A; Corbo M; Eleopra R; Filosto M; Giannini F; Granieri E; Bella V; Lunetta C; Mandrioli J; Mazzini L; Messina S; Monsurrò MR; Mora G; Riva N; Rizzi R; Siciliano G; Silani V; Simone I; Sorarù G; Volanti P; Lauria G
BMJ Open; 2017 Aug; 7(8):e015434. PubMed ID: 28801400
[TBL] [Abstract][Full Text] [Related]
16. Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series.
Ketabforoush AHME; Chegini R; Barati S; Tahmasebi F; Moghisseh B; Joghataei MT; Faghihi F; Azedi F
Biomed Pharmacother; 2023 Apr; 160():114378. PubMed ID: 36774721
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of mecasin for treatment of amyotrophic lateral sclerosis: A phase IIa multicenter randomized double-blinded placebo-controlled trial.
Kim S; Yang M; Ku B; Cha E; Seo W; Son I; Kang H; Kim D; Song B; Yang CS; Kim S
J Ethnopharmacol; 2023 Oct; 315():116670. PubMed ID: 37257710
[TBL] [Abstract][Full Text] [Related]
18. Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31].
Al-Chalabi A; Shaw PJ; Young CA; Morrison KE; Murphy C; Thornhill M; Kelly J; Steen IN; Leigh PN;
BMC Neurol; 2011 Sep; 11():111. PubMed ID: 21936930
[TBL] [Abstract][Full Text] [Related]
19. Macrophage-mediated inflammation and glial response in the skeletal muscle of a rat model of familial amyotrophic lateral sclerosis (ALS).
Van Dyke JM; Smit-Oistad IM; Macrander C; Krakora D; Meyer MG; Suzuki M
Exp Neurol; 2016 Mar; 277():275-282. PubMed ID: 26775178
[TBL] [Abstract][Full Text] [Related]
20. Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double-blind, placebo-controlled trial.
Beghi E; Pupillo E; Bianchi E; Bonetto V; Luotti S; Pasetto L; Bendotti C; Tortarolo M; Sironi F; Camporeale L; Sherman AV; Paganoni S; Scognamiglio A; De Marchi F; Bongioanni P; Del Carratore R; Caponnetto C; Diamanti L; Martinelli D; Calvo A; Filosto M; Padovani A; Piccinelli SC; Ricci C; Dalla Giacoma S; De Angelis N; Inghilleri M; Spataro R; La Bella V; Logroscino G; Lunetta C; Tarlarini C; Mandrioli J; Martinelli I; Simonini C; Zucchi E; Monsurrò MR; Ricciardi D; Trojsi F; Riva N; Filippi M; Simone IL; Sorarù G; Spera C; Florio L; Messina S; Russo M; Siciliano G; Conte A; Saddi MV; Carboni N; Mazzini L;
Eur J Neurol; 2023 Jan; 30(1):69-86. PubMed ID: 36148821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
